Abstract: The invention is concerned with novel Eimeria proteins with immunogenic properties as well as with DNA sequences encoding these proteins. These proteins can be administered to chickens thereby protecting the chickens against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.

Abstract: The present invention relates to a DNA encoding the human U.sub.1 -snRNP-A protein antigen, wherein said protein antigen is reactive towards an auto-antibody which is associated with an auto-immune disease, and the use of this protein in diagnostic tests relating to auto-immune diseases.

Abstract: The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Abstract: The present invention relates to a method for the elimination of false negative test results in assays for the detection of amplified analyte nucleic acid in a sample. Prior to amplification, an internal control is added to the sample, comprising a nucleic acid distinguishable from the analyte nucleic acid, that can be amplified with the same amplification reagents as the analyte nucleic acid. Preferably the internal control comprises a nucleic acid sequence corresponding to the analyte nucleic acid that has been mutated to discriminate it from the analyte nucleic acid.

Abstract: The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz?2,3:6,7!oxepino-?4 ,5-c!pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia.

Abstract: The invention relates to a composition comprising among others a fibrinopeptide A releasing compound. Furthermore the invention relates to the use of the composition as calibrator in plasma containing fibrinogen. A test kit comprising the said composition and a method to determine soluble fibrin also belong to the invention.

Abstract: This invention relates to a novel infectious bronchitis virus (IBV) serotype and to attenuated IBV strains derived therefrom, and also to live or inactivated vaccines made using such IB virus.

Abstract: The present invention provides the novel Newcastle disease virus strain C2 which is able to induce a solid immune response in poultry without adverse vaccination reactions.

Abstract: According to the present invention it has been found that a novel E. coli toxin or an immunogenic fragment thereof can be used in the preparation of vaccines for warm-blooded animals, and in particular for birds. Said toxin is found to be associated in flagellar structures attached to the bacteria, and these flagella or the free toxins can, after inactivation be used to immunize animals against E. coli infections.

Abstract: The invention relates to the use of antiglucocorticoid steroids for the manufacture of a pharmaceutical composition for the treatment of anxiety disorders.

Abstract: A steroid with a 17-spiromethylene lactone group having formula I ##STR1## wherein R.sub.1 is O, (H,H), (H,OR), or NOR, R being selected from H, (1-6C) alkyl and (1-6C) acyl; R.sub.2 is H, (1-6C) alkyl optionally substituted by a halogen, (2-6C) alkenyl optionally substituted by a halogen, (2-6C) alkynyl optionally substituted by a halogen, or halogen; R.sub.2 ' is H; or R.sub.2 ' together with R.sub.2 is a (1-6C) alkylidene group or a (2-6C) alkenylidene group; or R.sub.2 ' together with R.sub.3 is a bond; R.sub.3 is H if not together with R.sub.2 ' a bond; R.sub.4 is (1-6C) alkyl; one of R.sub.5 and R.sub.6 is hydrogen and the other is hydrogen or (1-6C) alkyl; X is (CH.sub.2).sub.n or (C.sub.n H.sub.

Abstract: The invention relates to a method of isomerisation of equilin or a derivative thereof to delta(8,9)-dehydro estrone ?delta(8,9)DHE!, characterized in that equilin or a derivative thereof is treated with a lithium salt of ethylenediamine or with lithium amide in dimethylsulfoxide.

Abstract: The present invention is concerned with the preparation of a pseudorabies virus (PRV) mutant, formed by a mutation in open reading frame 1 of the BamHI fragment 4. The invention also relates to a PRV mutant containing a heterologous gone encoding an antigen of a porcine pathogan, which is incorporated into ORF1 of the BamHI fragment 4 nucleic acid. Such a PRV mutant can be used as a vector vaccine to induce an immune response after infection in an appropriate host animal. In addition, the PRV mutant is suitable for distinguishing between animals infected by the vaccine virus and animals infected by naturally-occurring viruses.

Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmunoprecipitation of metabolically labeled gp160 from the same cell line.

Abstract: The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTLAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39 and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases to induce tolerance of the immune system. The autoantigen HC gp-39 and said peptides are also suitable to induce arthritis in non-human animals, preferably mice. The invention furthermore relates to pharmaceutical compositions comprising said autoantigen and/or said peptides, a diagnostic method for the detection of autoreactive T cells in a test sample and test kits to be used in said method.

Abstract: The invention relates to novel labelled modified oligonucleotides useful for anti-sense therapy, a conjugate of a targeting moiety, such as an antibody and a modified oligonucleotide complementary to the labelled oligonucleotide, the combination of both being useful in therapy of viral infections, tumours and (auto)immunodiseases. Also disclosed are pharmaceutical formulations comprising the various compounds.

Abstract: The present invention provides a combination vaccine for use in the protection of poultry against ND comprising an expression system, such as a virus vector, expressing a NDV immunogenic protein, and a live NDV vaccine strain. It is demonstrated that such a combination vaccine affords good local and systemic protection.

Abstract: The present invention provides a live and inactivated Chicken Anaemia Agent vaccine capable of evoking an immune response in a vaccinated chicken. The CAA virus of the vaccine is attenuated by serial passages in embryonated eggs.

Abstract: Disclosed are compounds of the formula: X Y Z A P Q T which are highly potent, selective factor IIa inhibitors, X, when present, may be connected to T, may be H, CH.sub.3, an acyl group, or a general protective group. Y is D-DPA, D-Phe, D-Val, D-Ile, D-Nle, a phenylsulfonyl, Dansyle, or 8-(1,2,3,4-tetrahydroquinolinosulfonyl) compound. Z, when present, is Gly, L/D-Pro, L/D-Ala, L/D-Leu, aminoisobutyric acid, a substituted or unsubstituted L/D-Pro ring homologue, or L/D-Val. A may be (I) wherein M is --CO--CF.sub.2 --(CO).sub.s --, --(CO).sub.d --NH--, --(CO).sub.d --(CH.sub.2).sub.p --, or --CH(OH)--(CH.sub.2).sub.p --, d is 0-2, p and q are 0-5, and s is 0 or 1, or A is a proline-like group. P and Q (if Q is present) are substituted or unsubstituted amino acids selected from the group consisting of L/D-Phe, L/D-Cha, L/D-Nal(1), L/D-Nal(2), L/D-phenylglycinyl, L/D-Leu, L/D-Ile, L/D-Nle, L/D-Arg, L/D-Lys, or L/D-His. T may be connected to X, or may be --OH, --OR.sup.4, --NH.sub.2, --NHR.sup.4, or --NR.sup.4 R.

Abstract: The invention relates to a steroid derivative which steroidal skeleton is bound at carbon atom 17 to a spiromethylene ring of the formula: ##STR1## wherein R.sub.a and R.sub.b are independently selected from the group consisting of hydrogen, methyl, and halogen; m is 1 or 2; and the asterisk denotes carbon atom 2 of the spiromethylene ring which is carbon atom 17 (or carbon atom 17.alpha. of a homosteroid skeleton) of the steroid. The steroids have progestational or antiprogestational activity.